Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Thursday, October 3, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, Inc. has announced its participation in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference. The company focuses on advanced gene editing using its proprietary ARCUS platform, which aims to develop therapies for complex gene edits, including the elimination of viral genes. This presentation underscores their commitment to innovation in gene therapy.
Price reaction · baseline $9.15 (2024-10-02 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
+4.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is utilizing an advanced gene editing platform.
  • The company is developing therapies for viral gene elimination.
  • Participation in a notable conference highlights their industry presence.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Oct. 3, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits including viral gene elimination, today announced that

Frequently Asked Questions

What is the focus of Precision BioSciences?

Precision BioSciences focuses on advanced gene editing therapies.

What platform does Precision BioSciences use?

They utilize the proprietary ARCUS platform for gene editing.

What conference will Precision BioSciences present at?

They will present at the H.C. Wainwright 5th Annual Viral Hepatitis Conference.

What is the goal of their gene editing therapies?

The goal includes developing therapies for viral gene elimination.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing viral hepatitis ARCUS platform
Last updated: Oct 3, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →